Stefan Glück, MD, PhD, FRCPC is medical oncologist and was V.P. Global Medical Affairs, at Celgene Corporation since October 2014 until December 2019. He oversaw oncology activities worldwide, as well as the Immuno-Oncology program in solid tumors and hematology. He also contributed to activities of Celgene around Early Assets. He previously served as a Sylvester Professor in the Department of Medicine at Miller School of Medicine, University of Miami, Florida until September 2014. From 2003–2008, he was the Clinical Director of the Braman Family Breast Cancer Institute, and from January 2009 - December 2010 Assistant Director of the Sylvester Comprehensive Cancer Center and Associate Chief, Division Hematology & Medical Oncology. He has been a PI of 37 clinical studies of breast cancer in Miami, as well as investigator in numerous scientific, translational projects. Before his move to Miami, Dr. Glück was Director of Southern Alberta Breast Cancer Program at the Tom Baker Cancer Center, a Professor in the departments of oncology, medicine, pharmacology & therapeutics at the University of Calgary, Alberta, Canada, and Deputy Head, Dept. of Oncology at the University of Calgary. He completed his medical studies at the Free University of West Berlin, Germany. The internship in Berlin was followed by residency in internal medicine and fellowship in hematology at the Heinrich Heine Universität in Düsseldorf, Germany, and a medical oncology & bone marrow transplant fellowship at the Princess Margaret Hospital, University of Toronto, Canada. Dr. Glück was presented the “America’s Top Oncologists” 2008 award from Consumers’ Research Council of America, as well as “Best Doctors in America” honor since 2006, and has annually earned that prestige every year to 2014. This award was warranted after less than 3 years of working in the United States.
He has authored or co-authored over 275 articles. In addition, Dr Glück has written or co-written several book chapters and numerous abstracts and has presented more than 500 papers at national and international meetings.
Professor Sophia Karagiannis is a translational B cell and cancer immunologist with academic and biotechnology experience in the USA and UK. Her cancer antibody discovery team focuses on dissecting the crosstalk between human immunity and solid tumours and understanding the impact of antibody isotype on antibody therapeutic efficacy for melanoma, ovarian and breast cancers. Research areas include cancer patient-derived B cells and their expressed antibodies, antibody-engaging immune effector cells such as monocytes/macrophages and basophils, and engineering antibodies of any specificity, class/isotype, Fc-optimised antibodies and antibody-drug conjugates. Sophia is founding member and Secretary of the AllergoOncology Working Group in the European Academy of Allergy and Clinical Immunology, focused on the interface between Th2 immunity, allergy, IgE and cancer. Her group is the first to design and translate IgE class antibodies to clinical testing. She is author of several patents and founder of Epsilogen Ltd, the first immuno-oncology company dedicated to developing IgE-based cancer immunotherapies.
Tullia C. Bruno, PhD, is an Assistant Professor in the Department of Immunology at the University of Pittsburgh and a faculty member in the Tumor Microenvironment Center and the Cancer Immunology and Immunotherapy Program at the UPMC Hillman Cancer Center. She obtained her Ph.D. in Immunology from Johns Hopkins in 2010 and completed her postdoctoral fellowship at the University of Colorado in 2015—both with a focus in tumor immunology. While Dr. Bruno’s PhD training focused on inhibitory receptors on intratumoral T cells, she became interested in tumor infiltrating B cells during her postdoctoral fellowship and has built her independent research program around understanding their function in multiple human cancers, in particular, lung and head and neck cancer. Dr. Bruno’s overall research objective is to develop a B cell-specific immunotherapy in the next five to ten years.
Diploma Thesis on B-Cell development at Max-Planck Institute for Immunobiology, Freiburg Germany PHD on molecular targeting of tumour cells over expressing the EGFR. Spend most of my professional career in immunoassay area
Dr. David Gilham first joined Celyad in April 2016 as member of the Scientific Advisory Board. As from September 1st, 2016, David became Vice-President R&D, heading the implementation of our Research and Development strategy for our programs in immuno-oncology. Dr. Gilham received his Ph.D in Molecular Pharmacology at the University of Dundee prior to moving to Bristol University in 1996 to work on CAR T cells with Professor Robert Hawkins. The group moved to Manchester in 1998 where his research activity has focused on engineering T-cells for cancer therapy and developing the necessary pre-clinical studies to support translation of this therapy into phase I/II clinical trials in Manchester. Prior to joining Celyad, David was a Reader in the Institute of Cancer Sciences, University of Manchester, UK and led the Clinical and Experimental Immunotherapy Group based within the Manchester Cancer Research Centre.
Dr John Maher is the scientific founder and chief scientific officer of Leucid Bio. He is also a clinical immunologist who leads the "CAR Mechanics" research group within King's College London. He played a key role in the early development of second generation (CD28) CAR technology while a visiting fellow at Memorial Sloan Kettering Cancer Center, an approach that has achieved clinical impact in haematological malignancies. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells, with a primary emphasis on solid tumour types. In addition, he is a consultant immunologist within King's Health Partners and Eastbourne Hospital.
Sheeba Irshad (KCL) is a CRUK Clinician Scientist with a translational research programme investigating the role of immunotherapies in chemotherapy resistant cancers. Sheeba is the translational lead and coordinating investigator for a translational trial platform with biomarker endpoints (PHOENIX). PHOENIX explores the potential interactions between DNA damage response inhibitors and immunotherapy in triple negative breast cancers. She is also the Clinical Deputy Head of the KCL Breast Cancer Now Unit responsible for the running of the breast cancer profiling translational research protocol.
Will is a Chartered (UK) and European Patent Attorney and has dealt with a wide range of subject matter in life sciences including fields such as immunology (especially antibodies, peptide vaccines and T-cell mediated immunology), molecular biology and medical devices (including stents and other implantable apparatus) and also non-medical subject matter such as plant biotechnology, DNA security tagging, and food technology. Will's work includes providing strategic advice, drafting and prosecuting patent applications, filing and defending Oppositions, the preparation of Appeals, advising on freedom to operate, and representing clients before the UK Patent Office and the European Patent Office (EPO). In particular, Will has prosecuted a very large number of patent applications in the biotechnology field at the EPO. This includes cases where he has been involved all the way from drafting the patent application, prosecuting it before the EPO, and defending it (successfully) in opposition so he has close-hand experience of the EPO's practice in biotechnology. Will attended Cambridge University where he read Natural Sciences. In his final year, he carried out research into Internal Ribosome Entry Sites in HCV. Will started in the patent profession in the mid-1990s and joined Marks & Clerk in 2007.
Before joining Pieris Pharmaceuticals as Director Immuno-Oncology overseeing pre-clinical development of Pieris´s innovative pipeline projects, Dr. Zettl was Project Leader at Boehringer-Ingelheim from 2011, leading antibody programs in the field of Immuno-Oncology from early preclinical into clinical phases. During his PhD and postdoctoral studies, he worked in a variety of areas of cancer biology at the EMBL in Heidelberg Germany and at the MRC-LMB in Cambridge UK. Research topics covered molecular mechanisms of how oncolytic viruses exploit the host cytoskeleton and the impact of metallo-protease (TACE) activation on cytokine and growth factor signalling with implications for cancer and inflammatory disorders. Dr. Zettl authored numerous high impact publications and patents in the field of Immuno-Oncology.
Renier Heijkants received his PhD from the Department of Cell and Chemical Biology of Leiden University Medical Centre, after which he left academia and joined APO-T B.V. as scientist. He has published papers in fields of oncology, apoptosis and molecular cell biology. APO-T’s goal is to develop effective therapeutics to combat cancer while preserving patients’ quality of life. Currently, as senior scientist at APO-T Renier devotes his time to supporting the R&D projects utilizing a unique truly cancer specific target, namely MAGE-derived peptide in context of MHC-I.
Sam Shrivastava is an accomplished biotech entrepreneur, business strategist, and investor. In 2016, Sam founded Venn Therapeutics, a highly innovative precision medicine company. Under his leadership as Chairman and CEO, a team of leading clinical immunotherapists and scientific inventors are developing a portfolio of novel, best-in-class integrin antibodies that are translating today’s most promising and innovative breakthroughs in cancer research into tomorrow’s life-saving treatments.
Mr. Shrivastava is also the Founder and Chairman of Ibis Therapeutics, which uses artificial intelligence and machine learning to build small-molecule drugs and repurpose existing drugs. Ibis is currently working with a team of immunologists and virologists exclusively focused on COVID-19. In all his endeavors, Mr. Shrivastava is deeply committed to improving patient health outcomes.
Mr. Shrivastava is the co-inventor on two provisional patents for small molecule discovery in immunology. He is currently enrolled in the High-Impact Cancer Research postgraduate certificate program at Harvard Medical School.
Dr Justyna Rzepecka obtained her PhD in the field of Immune Regulation from the University of Warsaw, Poland and the University of Humboldt, Germany in 2007. In 2008, she joined the group of Prof. William Harnett at the University of Strathclyde, Scotland focusing her research on exploring the therapeutic potential of small molecule drug candidates against allergic disorders and auto-immune diseases. Throughout her academic career, she authored or co-authored 18 publications in peer reviewed journals. In 2014, she moved to Aquila BioMedical where she established a suite of in vitro and ex vivo translational assays recapitulating tumour microenvironment. Now, as a Principal Scientist in Immunology, she is leading a team of senior scientists and scientists designing and executing novel and tailored client-led programmes at Aquila. Justyna’s greatest interest is in leading and delivering on specialised immunology projects to fight cancer and other immune-mediated diseases.
Professor Colin Self is CEO of Precision Immunotherapeutics Ltd, UK and Emeritus Professor at Newcastle University. His career largely focusses around the diagnostic and therapeutic uses of antibodies, their efficacy, their specificity and consequences of their clinical use. Following his desire to find means of increasing the specificity of therapeutic antibodies he developed and introduced the concept of light activation of antibodies with his early publication in Nature Medicine. This was followed by specific application to the human killer T-cell system wherein it was demonstrated that antibodies capable of achieving T-cell stimulation could be rendered inactive until illuminated by low intensity, long wavelength ultra-violet light. Thus T-cell activation could be stimulated within the body where and when required by illumination. This was taken forward by incorporation of the technology into bispecific antibodies, allowing anti-tumour antibodies to be fitted with a T-cell activating warhead that not only activated T-cells but did it only in the vicinity of targeted tumour, thus increasing the functional targeting specificity of the anti-cancer antibodies. He has now taken this forward with a new raft of technology aimed at the dramatic reduction of patient side-effects and welcomes collaboration.
Dr. Heckmann is a principal investigator at the USF Health Neuroscience Institute and serves as the director of the Center for Spatial Biology & Neuroimmunology with academic faculty appointments at the University of South Florida Morsani College of Medicine and the University of South Florida College of Engineering. In addition to his academic appointments, Dr. Heckmann is the Chief Scientific Officer at Asha Therapeutics. Dr. Heckmann’s major scientific discoveries and advancements include the discovery and characterization of LC3-associated endocytosis (LANDO) in immune regulation in neurodegenerative diseases, neuroinflammation, and neuro-oncology research published in journals including Cell and Science Advances. Dr. Heckmann has received multiple awards and honors including a Ruth L. Kirschstein National Research Service Award, a National Cancer Institute Award in Pediatric Oncology, an Excellence in Science Award from the AAAS, and is an International Fellow of the Royal Society of Medicine.
Dr. Manish Kumar is the product manager for cells and media at PromoCell and has several years of experience in the field of Human primary cell culture. Dr. Kumar did his PhD from the Max Planck Institute of Heart and Lung Research in Germany, where he worked on the biology of Lung Aging and COPD. His research work focused on how persistent DNA double strand breaks mediates pulmonary senescence in chronic obstructive pulmonary disease. He started his career as a strategy consultant and later delved to a career in product management. Since joining his current role at PromoCell, he leads the company’s strategy to offer the best possible Human primary cell culture products and a flexible, high quality service to PromoCell’s customers.
Dr. Marsilio Adriani is Principal Scientist at 4D pharma and has 20 years of experience in the field of basic and clinical immunology. Having gained his PhD in Naples, Italy, he joined first the NIH and later the Johns Hopkins University in US to worked at the characterization of Treg cells function in patients with autoimmunity and cancer. In 2012, Dr Adriani moved to UK to join UCL where he worked towards the identification of biomarkers able to predict the generation of anti-drug antibodies in patients with autoimmune diseases treated with biopharmaceuticals. He joined 4D Pharma in June 2018 leading the immunology group before joining the business development team in his current role.
Soldano Ferrone received his MD and PhD degrees in 1964 and in 1971, respectively, from the University of Milan, Milan, Italy. He has held faculty positions at the University of Milan, Milan, Italy, Scripps Clinic and Research Foundation, La Jolla, CA, Columbia University, New York, NY, New York Medical College, Valhalla, NY, Roswell Park Cancer Institute, Buffalo, NY and at the University of Pittsburgh School of Medicine, Pittsburgh, PA. Since 2012 he is a faculty member of the Department of Surgery at Massachusetts General Hospital, Harvard Medical School, Boston, MA. Dr. Ferrone’s research program focuses on the molecular characterization of escape mechanism(s) utilized by tumor cells to avoid immune recognition and destruction and on the development of combinatorial immunotherapeutic strategies to counteract the escape mechanism(s) utilized by tumor cells. These studies are greatly facilitated by the large panel of HLA antigen- and human tumor antigen-specific monoclonal antibodies he has developed and shared with the scientific community over the years.
Stefan Glück, MD, PhD, FRCPC is medical oncologist and was V.P. Global Medical Affairs, at Celgene Corporation since October 2014 until December 2019. He oversaw oncology activities worldwide, as well as the Immuno-Oncology program in solid tumors and hematology. He also contributed to activities of Celgene around Early Assets. He previously served as a Sylvester Professor in the Department of Medicine at Miller School of Medicine, University of Miami, Florida until September 2014. From 2003–2008, he was the Clinical Director of the Braman Family Breast Cancer Institute, and from January 2009 - December 2010 Assistant Director of the Sylvester Comprehensive Cancer Center and Associate Chief, Division Hematology & Medical Oncology. He has been a PI of 37 clinical studies of breast cancer in Miami, as well as investigator in numerous scientific, translational projects. Before his move to Miami, Dr. Glück was Director of Southern Alberta Breast Cancer Program at the Tom Baker Cancer Center, a Professor in the departments of oncology, medicine, pharmacology & therapeutics at the University of Calgary, Alberta, Canada, and Deputy Head, Dept. of Oncology at the University of Calgary. He completed his medical studies at the Free University of West Berlin, Germany. The internship in Berlin was followed by residency in internal medicine and fellowship in hematology at the Heinrich Heine Universität in Düsseldorf, Germany, and a medical oncology & bone marrow transplant fellowship at the Princess Margaret Hospital, University of Toronto, Canada. Dr. Glück was presented the “America’s Top Oncologists” 2008 award from Consumers’ Research Council of America, as well as “Best Doctors in America” honor since 2006, and has annually earned that prestige every year to 2014. This award was warranted after less than 3 years of working in the United States.
He has authored or co-authored over 275 articles. In addition, Dr Glück has written or co-written several book chapters and numerous abstracts and has presented more than 500 papers at national and international meetings.
Dr Stephen Harper is the Group Leader of Protein Engineering Research at Immunocore Ltd. He has been with the company since 2013. Using a combination of structure guided mutagenesis, molecular modelling and display approaches the group aims to provide tools/ scaffolds to engineer ImmTAC potency, specificity and stability. Stephen received his Ph.D. at the University of Sheffield and Postdoc at the University of Nottingham using crystallography to study protein-protein interactions.
Professor Sophia Karagiannis is a translational B cell and cancer immunologist with academic and biotechnology experience in the USA and UK. Her cancer antibody discovery team focuses on dissecting the crosstalk between human immunity and solid tumours and understanding the impact of antibody isotype on antibody therapeutic efficacy for melanoma, ovarian and breast cancers. Research areas include cancer patient-derived B cells and their expressed antibodies, antibody-engaging immune effector cells such as monocytes/macrophages and basophils, and engineering antibodies of any specificity, class/isotype, Fc-optimised antibodies and antibody-drug conjugates. Sophia is founding member and Secretary of the AllergoOncology Working Group in the European Academy of Allergy and Clinical Immunology, focused on the interface between Th2 immunity, allergy, IgE and cancer. Her group is the first to design and translate IgE class antibodies to clinical testing. She is author of several patents and founder of Epsilogen Ltd, the first immuno-oncology company dedicated to developing IgE-based cancer immunotherapies.
Dr. Angela Vasaturo is the Director of Scientific Affairs at Ultivue. Prior to Ultivue, Angela was a Senior Researcher in Dr. Jerome Galon’s Laboratory of Integrative Cancer Immunology at the Cordeliers Research Center. In 2012, Angela was among the first postdocs in Europe to be involved in the development of multiplex IHC and multispectral imaging and analysis of up to six immunofluorescence markers, and today is considered a leading European expert in multiplex IHC techniques, digital pathology, spatial biology and tissue imaging.
Ann obtained her PhD at the MRC Clinical Research Centre, Harrow in 1991 then spent 10 years in Texas working on the molecular mechanisms of lipoprotein assembly, secretion and metabolism, first as a post-doc at the Southwest Foundation for Biomedical research in San Antonio, and then as Assistant Professor at UT Southwestern in Dallas. She returned to the UK in 2001 and, after a 4 year career break with her children, joined Professor Martin Glennie at the University of Southampton in 2005 to work on monoclonal antibody (mAb) based cancer therapeutics. Her main focus was development of agonistic CD40 antibodies (Cancer Cell (2015) 27:138; Cancer Cell (2018) 33:664). Ann joined UCB in 2016 where she continues to pursue her interest in antibody based cancer therapies as well as therapeutics for targeting autoimmune disease.
Aude De Gassart is director of preclinical research at ImCheck. She spent 15 years in academic research (Pr. Philippe Pierre Lab, CIML, Marseille, France; Pr. Fabio Martinon Lab, Biochemistry Department, Lausanne Switzerland) focussing on cell biology and immunology (antigen presentation, stress response and immuno-oncology). She joined ImCheck in 2017 and led the preclinical development of ICT01, the first anti-BTN3A antibody activating gd T cells to entering the clinic in 2020. She is responsible for the preclinical development of a pipeline of new antibody therapeutic candidates targeting butyrophilins, a new superfamily of immunomodulator molecules.
Dr Ali Roghanian is an Associate Professor in Cancer Immunology & Immunotherapy at the University of Southampton, UK. Ali obtained his PhD degree in immunology from the University of Edinburgh in 2007. He specialises in experimental models of cancer, such as humanised mouse models, as well as developing and investigating the MoA of novel therapeutics. Following a postdoctoral position at Cambridge University (2006-2008), he joined the University of Southampton in 2009, where he was a lead scientist on a key translational project, which involved extensive characterisation of novel human FcγRIIB monoclonal antibodies (mAb) in collaboration with a biotech company. The lead candidates (BI-1206 and BI-1607) are currently in Phase I/IIa clinical trials for treatment of haematological and solid malignancies with promising prospects. In 2015, Dr Roghanian was awarded a highly competitive Visiting Fellowship to spend 2.5 years at MIT, USA, before relocating to Southampton in 2018 to establish his independent research group at the Centre for Cancer Immunology
Lindy is a Professor of Cancer Immunotherapy at the University of Nottingham and CSO of Scancell Ltd. She has developed a panel of mabs recognised tumour associated glycans and has pioneered a new antibody engineering technology which enhances the avidity of mabs, termed Avidimabs. This has been applied to the anti-glycan mabs resulting in direct killing mabs. These mAbs are also good at drug delivery making strong ADCs with duocarmycin and PBD payloads. She has developed two vaccine platforms ImmunoBodyTM and ModitopeTM which induce potent killer CD8 T cells and cytotoxic CD4 T cells to post-translational modifications respectively. The first ImmunoBodyTM, SCIB1, has completed a phase I/II clinical trial in which 14/16 patients with melanoma have been disease-free for five years. The first product from the ModitopeTM platform will enter the clinic next year. Lindy has over 150 peer-reviewed publications and is also the inventor of 66 patents. She was awarded the Waldenstrom Prize for cancer Immunotherapy in 2019.
Deya’s research focuses on biomarkers discovery and translational medicine in the areas of female infertility and gynaecological cancers. She has applied her expertise in inflammation, angiogenesis, vascular permeability, reproductive biology and cell to cell interactions to develop multicellular 3D models for use as tools in biomarker discovery and drug development. Her projects involve collaborations with the private sector to expedite validation of clinical diagnostic biomarkers and the development of new drug leads for targeted cancer therapy including Antibody Drug Conjugates and Exosomes. She is a co-PI of the Smart Expertise project CEAT-Cluster for Epigenomics and ADC therapeutics (£2.6M), where she leads the ADC programme. Deya is the South West Wales (Non-Clinical) lead within the Wales Cancer Research Centre, and Chair of Swansea University Medical School Research Ethics and Governance. She teaches within the undergraduate and postgraduate programmes at Swansea University Medical School. Deya is passionate about patient participation In research engaging the public, from families to patients, with her work by hosting regular public engagement events.
I completed my Ph.D. under the supervision of Jacques Nunes and Daniel Olive at the University of the Mediterranean, Marseille, France, focusing on the negative regulation of primary and leukemic T cell activation. I undertook postdoctoral training at the Netherlands Cancer Institute in Amsterdam with John Collard, where I studied polarity proteins and T cell migration. I then moved on to the laboratory of Matthew Krummel at UCSF, USA, where I studied the molecular mechanism of T cell migration in vivo using 2-photon microscopy. In addition, I developed an interest in the collective behaviour of T cells. I joined the Kennedy Institute in June 2016, where I am exploring the negative feedbacks and crosstalk regulating the T cell response, and how this is co-opted by cancer to evade the immune system.
Marcello Stein Ph.D. received his doctoral degree in immunology and genetics from the University of Erlangen-Nuremberg, Germany in 2011. After two years of post-doctoral studies at the Department of Immune Modulation at the University Hospital Erlangen, and three years as Product Manager Life Science at Peqlab Biotechnologie GmbH and VWR International AG, Dr. Stein joined Miltenyi Biotec as Global Product Manager and Group Leader Immunology T cells in the marketing department. His team focuses primarily on the translational research T cell product portfolio and covers amongst others workflows for CAR T cell research, antigen-specific T cells and regulatory T cells.
Maik Pruess, Senior Field Application Scientist (FAS); Personalis, Germany
Since 2020: Senior Field Application Scientist (FAS); Personalis, Inc.
2018 – 2020: Field Application Specialist; Agena BioScience GmbH
2013 – 2018: Sr. Field Application Scientist & Prosigna Trainer EMEA, Nanostring, Inc.
Maik has done his diploma in Biochemistry from Berlin.
Dr. Korn is one of our most recognized board-certified and fellowship-trained radiologists. Dr. Korn specializes in Nuclear Medicine and Cancer Biology with extensive involvement in clinical research as both a study investigator and clinical publication author that has afforded him in-depth knowledge of the common pitfalls and complex challenges associated with clinical trials. Dr. Korn has received public recognition and awards from the American Society of Clinical Oncology, American College of Radiology Imaging Network, Ibis Foundation of Arizona, and received the Top Doctor Award for Radiology and Nuclear Medicine. As Imaging Endpoints’ Chief Medical Officer, Dr. Korn provides the medical perspective, oversight, and leadership that is critical to the services we provide.
Prof Sanz-Moreno received a degree in chemistry and a master's degree in biochemistry (University of Oviedo, Spain), followed by a PhD in chemical sciences (University of Cantabria). She joined the Institute of Cancer Research in London as a Marie Curie Intra-European Fellow to work with Prof Chris Marshall. In 2008, she received the Applied Biosystems and EACR 40th Anniversary Research Award. In 2011, Victoria started her independent group and received a CRUK Career Development Fellowship at King's College London. In 2015, she was highly commended as CRUK Communications and Brand Ambassador. In 2017, Victoria was awarded the BSCB Women in Cell Biology Early Career Award Medal. The same year, she received a CRUK Senior Fellowship and was badged Werth Trust Fellow. In 2018, Victoria joined Barts Cancer Institute (BCI-QMUL) as Professor of Cancer Cell Biology. In 2019, she received The Distinguished Alumnus Award from Colegio Inmaculada (Asturias) and Paper of the Year Award at BCI.
Archie is a final year PhD student at UCL, working under the supervision of Dr Jamie Baker and Prof. Vijay Chudasama. His work focusses on the design of Next-Generation Maleimide (NGM) reagents to site-selectively modify proteins and peptides, for applications as novel therapeutics and diagnostic agents. The Baker and Chudasama groups have developed optimised methods for the efficient re-bridging of disulfides in order to create superior ADCs. Recently, the group has published on topics such as site-selective lysine modification via Cysteine-to-Lysine transfer, novel strategies to achieve heterobifunctional dual conjugates and chemically constructed bispecifics.
Dr. Ben Xu is an expert in biologics discovery and development. In GenScript he accumulated broad hands-on experience on therapeutic antibody development, gene & cell therapy, bioprocess development and IND enabling studies. With his solid knowledge background, Dr. Xu is good at providing practical biologics development solutions with very high performance/price ratio.
Dr. Mustapha Faroudi is a Director for IO projects at Biomunex Pharmaceuticals. Mustapha oversees Biomunex programs to develop modular BiXAb antibodies for therapeutic application including immune-oncology. Prior to joining Biomunex, Mustapha had worked at F-star Therapeutics, where he was involved in the preclinical and clinical development of bispecific antibodies. Mustapha obtained his PhD in Immunology from University of Toulouse III (Paul Sabatier), France and post-doctoral trainings from NIMR (London, UK) and CIML (Marseille, France).
Idhnan Hussain is the Flow cytometry technical specialist for Thermo Fisher in London. Having previously worked for Ebioscience, Affymetrix and now with Thermo Fisher, he has years of experience in Flow Cytometry. Idhnan is keen to work alongside scientists to provide innovative and efficient solutions to help advance science and research.
Immediate past president of PHC Corporation of North America. Currently working as a catalyst in the field to create new global business opportunities for PHC business units and PHCHD subsidiary companies. Working directly with pharmaceutical companies, government agencies, academic institutions, and the investment community; providing them with Medical Device, Lifescience, and Healthcare IT solutions. Steven’s extensive experience working in Southeast Asia (Philippines, Singapore) and Japan allows him to bring a unique background of knowledge which helps PHC Group businesses grow faster organically and inorganically while achieving the corporate mission of creating healthcare solutions that have a positive impact and improve the lives of people. Current role is head of BD&L, Anatomical Pathology for PHC Group.
Jennifer is a Board of Registry certified Histotechnologist with the American Society of Clinical Pathology, with over 20 years in histology, immunohistochemistry, and molecular and cellular biology. She earned her Bachelor’s degree in Biomedical Science from Western Michigan University and her Masters of Science degree in Biotechnology from Johns Hopkins University. Jennifer has worked in clinical histology and research histology laboratories, as well as research & development, quality, technical consulting, and now serves as a global market development manager for Epredia.
Grace Robinson has extensive experience leading strategic marketing and product management initiatives in the government contracting, pharmaceutical, and life sciences industries. In her current role as a Global Market Development Manager she is responsible for the automated archiving product line, featuring the Arcos™ block management and ArcosSL™ slide management systems from Epredia. Grace has a BS in Communications and Technical Writing from James Madison University. She lives in Mt. Pleasant, SC with her husband and daughter.
James Watson is the imaging and detection specialist for Thermo Fisher in London. Having worked in the commercial side of the life science industry for over 10 years he is passionate about bringing novel technologies and solutions to scientists in biomedical research.
.jpg)
Nicola is the Global Scientific Liaison for Horizon Discovery Ltd., where she has worked for the past 6 years. Nicola’s role involves scientific input to the wider business on the use of gene editing and gene modulation and how this can best be used to aid Pharmaceutical companies in the pursuit of new therapeutic targets in a variety of diseases. Prior to working at Horizon Discovery, Nicola worked for Nature Publishing Group (now Springer Nature) as an Associate, Senior and Chief Editor for Nature Reviews Cancer. Nicola has 10 years of postdoctoral research experience studying apoptosis (programmed cell death) in the context of cancer research and cardiovascular research and studied human anatomy for her B.Sc. and programmed cell death for her Ph.D. at the University of Birmingham, UK.
Eden Kleiman currently works at Crown Bioscience in San Diego as a Study Director / Senior Scientist developing and executing Immuno-Oncology client studies with an emphasis on cancer cell line / PBMC co-culture killing assays and antigen-based T cell recall assays. Eden migrated to Crown from parent company JSR Life Sciences where he helped develop a novel variant of the PBMC-based antigen recall assay incorporating adenosine to test adenosinergic pathway inhibitors. He was also involved in developing MBLI’s tetramers for use in single cell sequencing applications. Prior to joining JSR, Eden was a post-doctoral fellow at Scripps Research Institute in La Jolla where he studied mechanisms of B cell differentiation and B cell receptor diversification.
